The overexpression and activation of the MET receptor tyrosine kinase has been identified in many human malignancies, but its role in canine cancer has only been minimally investigated. In this study we evaluated the expression of MET in two canine malignant melanoma (CMM) cell lines as well as in 30 CMM tissue samples that were collected from the clinical service at our institution. We were able to confirm the expression of the MET protein in both melanoma cell lines, and we demonstrated MET activation by its ligand, HGF, through phosphorylation, in Western blot analysis. We were also able to demonstrate, by immunohistochemistry, the expression of MET in 63% of the tumor tissue samples analyzed, with the majority demonstrating a relatively low expression profile. We then evaluated the association of MET expression scores with histologic parameters, metastasis, and survival. While statistically significant associations were not found across these parameters, an inverse relationship between MET expression levels and time to lymph node versus distant metastasis was suggested in our cohort. These findings may require assessment in a larger group of specimens to further evaluate the role of MET expression in the homing of metastasis in lymph nodes versus that in distant organs.
|Original language||English (US)|
|State||Published - Apr 2023|
Bibliographical noteFunding Information:
This research was funded by a Fall 2019 Resident Research Grant from the American College of Veterinary Internal Medicine (ACVIM), sponsored by Purina Institute, grant ID # 775260. This study has not been reviewed or endorsed by the ACVIM, and the views expressed do not necessarily reflect the views of the ACVIM, its officers, directors, affiliates, or agents.
© 2023 by the authors.
- canine malignant melanoma
- prognostic value
- tyrosine kinase receptor